Professor Salim Abdool Karim, FRS, is a clinical infectious disease epidemiologist who is widely recognised for his research contributions in HIV prevention and treatment. He is Centre for the Aids Programme of Research in South Africa (CAPRISA) Professor for Global Health in the Department of Epidemiology at the Mailman School of Public Health at Columbia University. He is also Director of the Centre for the AIDS Program of Research in South Africa (CAPRISA), Pro-Vice-Chancellor (Research) at the University of KwaZulu-Natal in Durban, South Africa and Adjunct Professor of Medicine at Weill Medical College of Cornell University. His contributions to microbicides for HIV prevention spans two decades and culminated in the Centre for the Aids Programme of Research in South Africa (CAPRISA) 004 tenofovir gel trial which provided proof-of-concept that antiretroviral drugs can prevent sexually transmitted HIV infection and herpes simplex virus type 2 in women. He is co-inventor on patents that have been used in several HIV vaccine candidates and his clinical research on TB-HIV treatment has shaped international guidelines on the clinical management of co-infected patients. He is Chair of the UNAIDS Science Expert Panel, Chair of the World Health Organization (WHO)'s HIV and Hepatitis Scientific and Technical Advisory Group, and a member of the World Health Organization (WHO) HIV-TB Task Force. He is an elected Fellow of the World Academy of Sciences, the African Academy of Sciences, the Academy of Science in South Africa, the Royal Society of South Africa, and the American Academy of Microbiology. He is a Foreign Associate Member of the United Station National Academy of Medicine. He serves on the Boards of the New England Journal of Medicine, Lancet-Global Health, Lancet-HIV, and the Journal of AIDS.
Brief Biography (English)